Evaluation of Anti-Thyroid Peroxidase Antibody Levels In Patients With Metabolic Syndrome

Sibel Serin1, Hakan Kocoglu2, Yildiz Okuturlar2, Asuman Gedikbasi2, Irem Kirac Utku2, Esra Demir2, Ezgi Ersoy Yesil1, Guven Koç1, Tulay Eyupgiller1, Sema Ucak Basal1, Ozlem Harmankaya4

1Department of Internal Medicine, Umraniy Education and Research Hospital, Istanbul, Turkey
2Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey
3Division of Nephrology, Umraniy Education and Research Hospital, Istanbul, Turkey

OBJECTIVES

This study aimed to evaluate thyroid stimulating hormone (TSH) and anti-thyroid peroxidase antibody (anti-TPOab) levels in euthyroid subjects with metabolic syndrome (MetS) and to compare them with healthy subjects without MetS.

METHODS

Study included 173 subjects consisted of 96 subjects with MetS and 77 healthy controls. Gender, age, body mass index (BMI), waist circumference (WC), and detailed medical history of all participants were noted. Serum insulin, glucose, “Homeostatic Model Assessment- Insulin Resistance” (HOMA-IR), total cholesterol (TC-HOL), low density lipoprotein (LDL-CHOL), high density lipoprotein (HDL-CHOL), triglyceride (TG), TSH, free T4, and anti-TPOab levels were obtained.

RESULTS

TSH and anti-TPOab levels were significantly higher in the MetS group than control group (p = 0.048 and p = 0.001, respectively). A ROC curve for anti-TPOab to discriminate between patients with MetS and controls was determined at ≥ 16.4 IU/mL (sensitivity 89.58%; specificity 80.52%; positive predictive value 85.15%; negative predictive value 86.11%; p = 0.001). Odds ratio for anti-TPOab ≥ 16.4 IU/mL between MetS and control group were 35.547 (95% confidence interval [CI] 14,979-84,357).

CONCLUSIONS

Serum TSH and anti-TPOab levels were significantly higher in euthyroid subjects with MetS than those without MetS. Subjects with MetS who had anti-TPOab levels ≥ 16.4 IU/mL had 8.9-fold risk of having higher than normal BMI; 7-fold risk of having HT; 11-fold risk of having higher than normal HOMA-IR; 2-fold higher incidence of family history of CAD; and 4-fold risk of having HT.

REFERENCES: